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CXCR3-Mediated Skin Homing of Autoreactive
CD8 T Cells Is a Key Determinant in Murine
Graft-Versus-Host Disease
Vadim A. Villarroel1, Naoko Okiyama1, Gaku Tsuji1, Jay T. Linton1 and Stephen I. Katz1
The pathomechanisms underlying the development of cutaneous graft-versus-host disease (GVHD) are
incompletely defined. We previously reported that K14-mOVA mice expressing membrane ovalbumin (mOVA),
driven by the keratin 14 (K14) promoter, developed GVHD-like mucocutaneous disease and weight loss following
transfer of OVA-specific, CD8þ OT-I T cells. In this study, we demonstrate that early in the course of disease, the
kinetics of epidermal expression of C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10, interferon-g-inducible
chemokines that bind the C-X-C motif chemokine receptor 3 (CXCR3) receptor, coincides with CXCR3 expression
by OT-I cells in secondary lymphoid organs. Recruitment of OT-I cells into the skin began by day 5 with
progressive accumulation through day 13 post transfer. Transfer of CXCR3-knockout (CXCR3KO) OT-I cells into
K14-mOVA mice resulted in strikingly attenuated skin disease. CXCR3KO OT-I cells retained full activation and
effector function, but preferentially accumulated in the spleen, in contrast to wild-type (WT) OT-I cells that
accumulated in skin-draining lymph nodes. Moreover, OT-I cells accounted for a significantly reduced percentage
of skin-infiltrating lymphocytes in mice receiving CXCR3KO OT-I cells compared with WTOT-I cells. These results
identify CXCR3 as being critical to the skin-selective effector T-cell recruitment underlying autoreactive GVHD,
suggesting CXCR3 as a potential target in the treatment of GVHD and related skin diseases.
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INTRODUCTION
We have previously described a reproducible model of graft-
versus-host disease (GVHD)-like disease that can be used to
explore mechanisms of cutaneous injury initiated by defined
CD8 effector T cells targeting basal keratinocytes. Transgenic
K14-mOVA mice expressing a model antigen, such as mem-
brane chicken ovalbumin (mOVA), under control of the
keratin 14 (K14) promoter, develop mucocutaneous inflam-
mation and weight loss following the transfer of CD8þ OT-I T
cells recognizing OVA peptide associated with MHC (major
histocompatibility complex) class I. Recapitulating the skin
changes of acute GVHD in human beings, lesional skin
histology depicts acanthosis, basal vacuolar degeneration,
exocytosis, dyskeratosis, and dermal lymphocytic infiltration
(Shibaki et al., 2004). Our model is, thus, well suited to
examine the pathobiology of human diseases in which skin-
directed CD8þ effector T cells are implicated, including
lichen planus, discoid lupus, erythema multiforme, and
GVHD. Historical murine models of GVHD as well as some
human bone marrow transplantation protocols have focused
on MHC mismatches and required radiation or chemical
conditioning or both; however, our murine model of acute
GVHD-like disease does not require conditioning for the
development of disease (Schroeder and DiPersio, 2011;
Wysocki et al., 2005). The lack of the need for a
conditioning regimen leads to a limited degree of a cytokine
storm that may occur as a consequence of the conditioning.
Several murine models of acute and chronic GVHD have
been described, along with their strengths and limitations that
have been extensively reviewed elsewhere (Schroeder and
DiPersio, 2011).
Although the skin is the most commonly involved target
organ in GVHD, the pathomechanisms governing skin selec-
tivity are incompletely characterized. Keratinocytes elaborate
diverse cytokines and chemokines to subserve qualitatively
distinct physiological functions, ranging from priming antigen-
specific autoreactive CD8þ T cells to recruiting leukocytes in
skin inflammation (Kim et al., 2009). We hypothesized that
epidermal chemokine expression and skin-directed influx of
activated T cells expressing cognate antigen receptors is an
early, fundamental pathomechanism underlying GVHD-like
skin disease. In this report, we show that two interferon (IFN)-
g-inducible chemokines, C-X-C motif chemokine ligand 9
(CXCL9) and CXCL10, are highly expressed in the epidermis
of K14-mOVA mice early after OT-I transfer and that
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their common receptor, C-X-C motif chemokine receptor 3
(CXCR3), is highly upregulated on OT-I cells before skin
lesions manifest.
CXCR3 and its associated ligands, comprising the CXCR3
axis, have been associated with cardiac, lung, and skin
allograft rejection and autoimmune diseases, including arthri-
tis and type 1 diabetes (Belperio et al., 2003, Li et al., 2010,
Melter et al., 2001, Laragione et al., 2011, Frigerio et al.,
2002). In studies of skin disease, we previously reported that
CXCL10 expression was induced in keratinocytes following
sensitization during contact hypersensitivity (Enk and Katz,
1992). CXCR3-deficient mice show prolonged T helper type 1
(Th1)-type contact hypersensitivity and poorly control cutaneous
Leshmaniasis (Suga et al., 2013, Rosas et al., 2005). CXCL10
upregulation is also thought to contribute to CXCR3þ
lymphocyte accumulation in alopecia areata (McPhee et al.,
2012, Ito et al., 2013). In addition, CXCR3 ligands were highly
expressed in erythema migrans and acrodermatitis chronica
atrophicans skin lesions (Mu¨llegger et al., 2007). Conversely,
in melanoma, intratumoral chemokine expression of
CXCL9–10 has been exploited to increase T-cell infiltration
and facilitate tumor control (Hong et al., 2011).
In acute GVHD patients, basal keratinocytes have been
shown to express CXCL10, and dermal T-cells that were
CXCR3þ (Piper et al., 2007). Although clinical data suggest
that CXCR3 ligand–mediated lymphocyte recruitment is
involved in the pathogenesis of cutaneous GVHD (Wenzel
and Tu¨ting, 2008), only one study to date has included the
skin in studies of CXCR3 in GVHD, showing that long-term
systemic treatment with anti-CXCR3 antibody reduced liver,
intestine, and skin inflammation (He et al., 2008). In this
study, we directly confirmed the functional role of CXCR3 in
skin-targeted homing of autoreactive T cells during cutaneous
GVHD, using gene targeting of CXCR3 on cloned,
autoantigen-specific CD8 effector T cells to elucidate its
significance. Our findings demonstrate that CXCR3-mediated
cell migration is a key determinant in the cutaneous
recruitment of autoreactive T cells, validating the notion that
selectively targeting CXCR3 may have its uses in the treatment
of GVHD and other CD8þ T cell–mediated skin diseases.
RESULTS
CXCL9 and CXCL10 mRNAs are upregulated in the epidermis of
K14-mOVA mice during GVHD-like disease
To identify chemokines mediating cutaneous OT-I cell recruit-
ment, epidermal sheets were created from K14-mOVA mice
that were adoptively transferred with OT-I cells, and quanti-
tative real-time PCR (qRT-PCR) was used to profile mRNA
expression kinetics for 29 chemokines. Consistent with a
GVHD model identifying CXCL9 and CXCL10 among 314
genes upregulated 1 week after allogeneic transplantation
(Sugerman et al., 2004), qRT-PCR results showed that
CXCL9 and CXCL10 mRNAs were highly expressed in the
epidermis of K14-mOVA mice following OT-I transfer versus
control untreated K14-mOVA mice. CXCL9 and CXCL10
mRNAs were induced as early as 2 days after OT-I transfer
and progressively increased, peaking 5 days post transfer and
returning to basal levels after day 12 (Figure 1a). Early
infiltration (at two days) of activated interferon-producing
OT-I cells probably accounts for the early upregulation of
CXCL9 and CXCL10 mRNAs (Supplementary Figure S1
online). Establishing keratinocytes as the primary epidermal
source of CXCL9 and CXCL10, CD45-depletion of epidermal
suspensions did not reduce CXCL9–10 expression (data not
shown). CXCL9 and CXCL10 have been associated with
cutaneous immunopathogenesis in lichen planus, chronic
discoid lupus erythematosus, and GVHD patients (Wenzel
and Tu¨ting, 2008, Wenzel et al., 2008), suggesting a
chemotactic role for CXCL9–10 in the pathogenesis of
GVHD-like skin disease in our model.
CXCR3 is primarily expressed on CD3þ and CD11cþ cells in the
skin-draining lymph nodes (SDLNs) during GVHD-like disease
CXCR3 expression has been detected on T cells, NK cells, NK
T cells, dendritic cells, B cells, and regulatory T cells (Groom
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Figure 1. Expression of C-X-C motif chemokine receptor 3 (CXCR3) ligands,
C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10, in the epidermis and
expression of CXCR3 on T cells in the skin-draining lymph node (SDLN) of
keratin 14–membrane ovalbumin (K14-mOVA) mice after OT-I transfer.
(a) Summary of CXCR3 ligand expression in the ear epidermis of K14-mOVA
mice after transfer of 1106 OT-I cells as determined by quantitative real-time
PCR (n¼ 2–3 mice per day). Fold changes versus control epidermal mRNA
from untreated K14-mOVA mice are shown. Three independent experiments
were performed. (b) Summary graphs of the percentages of CXCR3þ cells on
gated lymphocyte subsets in SDLNs of K14-mOVA mice that were collected
3–7 days after transfer of 1 106 OT-I cells. Bars represent pooled samples
stained for fluorescence-activated cell sorting analysis (n¼ 3–4 mice per day).
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and Luster, 2011). As CXCR3 involvement in Th1-mediated
immune responses has been demonstrated, we hypothesized
that CXCR3 would be expressed by CD3þ (Qin et al., 1998)
cells in the SDLNs during GVHD-like disease. To define
CXCR3-expressing leukocyte subsets, CXCR3 expression was
examined on leukocytes isolated from the SDLNs of K14-
mOVA mice between day 3 and day 7 post OT-I transfer.
CXCR3 was primarily detected on CD3þ and CD11cþ cells
in SDLNs, peaking on day 5 with approximately 20% of
CD3þ lymphocytes expressing CXCR3 (Figure 1b). Parallel
expression kinetics of CXCR3 ligands in the epidermis and
CXCR3 on SDLN T lymphocytes implicated CXCR3 in skin-
directed effector T-cell trafficking.
CXCR3 is preferentially expressed on antigen-specific,
autoreactive OT-I cells
To further characterize CD3þCXCR3þ lymphocytes in the
SDLNs, GFPþOT-I cells were transferred into K14-mOVA
mice. Fluorescence-activated cell sorting (FACS) analysis of
CD3þCD8þ -gated lymphocytes in the SDLNs and spleens
from K14-mOVA mice showed that CXCR3 was expressed on
a significantly greater percentage of GFPþ , antigen-specific,
donor OT-I cells compared with endogenous recipient, CD3þ
CD8þGFP lymphocytes (Figure 2a and b). By 5 days after
the OT-I cell transfer, 495% of the GFPþOT-I cells in SDLNs
expressed CXCR3 (Figure 2a). Between day 3 and day 5,
although the proportion of CD3þCD8þGFP endogenous
CXCR3þ lymphocytes remained relatively constant, the pro-
portion of CD3þCD8þGFPþ -gated lymphocytes increased
(Figure 2a and b). Robust CXCR3 expression on OT-I cells in
the SDLNs suggested that OT-I cells migrated to the skin in
response to epidermal CXCL9 and CXCL10 expression.
GFPþOT-I cells are recruited to the skin by 5 days after transfer
into K14-mOVA mice
The kinetics of OT-I cell egress from the SDLNs and OT-I cell
recruitment to the skin were also studied using GFPþOT-I
cells. Results revealing elevated epidermal CXCL9 and
CXCL10 expression and CXCR3 expression on OT-I cells
provoked the hypothesis that cutaneous infiltration of OT-I
cells proceeded via CXCL9–10-mediated chemotaxis. We
thought that the appearance of GFPþOT-I cells in the skin
could lead to a reduction in the proportion of GFPþOT-I cells
in SDLNs, reflecting OT-I recruitment to target organs includ-
ing the skin. To test this, GFPþOT-I cells were transferred to
K14-mOVA mice, and SDLNs were collected for FACS
analysis between day 6 and day 14 after OT-I cell transfer.
In accordance with previous studies (Miyagawa et al., 2008),
the proportion of GFPþOT-I cells in the SDLNs of K14-mOVA
mice gradually decreased after day 6 post OT-I transfer, and
by day 14, o1% of CD3þCD4CD8þ lymphocytes in
SDLNs were OT-I cells (Figure 3a). To evaluate the dynamics
of skin infiltration by OT-I cells, GFPþOT-I cells were
transferred into K14-mOVA and C57BL/6 control mice, and
ear skin–infiltrating lymphocytes were analyzed by FACS.
GFPþOT-I cells were first detected at day 5 post-OT-I transfer,
when they were increased in proportion and persisted beyond
day 13, whereas no GFPþOT-I cells were detected among
skin-infiltrating lymphocytes collected from C57BL/6 control
mice (Figure 3b). The appearance of GFPþOT-I cells in the
skin 5 days after OT-I transfer corresponded to maximal
epidermal CXCL9–10 mRNA expression as evinced by qRT-
PCR. In concert, the pathodynamics of GFPþOT-I cell
trafficking indicated the significance of CXCR3-orchestrated
skin recruitment of OT-I cells.
Absence of CXCR3 on OT-I cells markedly attenuates skin
disease in K14-mOVA mice but does not affect the magnitude of
weight loss
We hypothesized that functional interactions between CXCR3
and its ligands were necessary for efficient recruitment of OT-I
cells to skin. As a corollary, we anticipated that the transfer of
CXCR3-knockout (CXCR3KO) OT-I cells into K14-mOVA
mice would diminish the severity of autoreactive skin disease
as a result of impaired OT-I migration to the skin. CXCR3KO
or wild-type (WT) OT-I cells were injected intravenously into
K14-mOVA mice. K14-mOVA mice that received CXCR3KO
OT-I cells showed a profound reduction in the extent of
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Figure 2. C-X-C motif chemokine receptor 3 (CXCR3) is more frequently
expressed by OT-I cells compared with endogenous CD8þ lymphocytes in
skin-draining lymph nodes (SDLNs) of keratin 14–membrane ovalbumin
(K14-mOVA) mice. (a, b) Summary of flow cytometry data of percentages of
CXCR3þ based on GFP expression on CD3þCD4þCD8þ -gated lymphocytes
in the SDLNs (a) and spleens (b) of K14-mOVA mice 3 days and 5 days (n¼ 4
mice per day) after transfer of 1 106 GFPþOT-I cells. GFPþ cells represent
OT-I cells, and GFP cells represent endogenous CD8þ T cells. Error bars
indicate meanþ1 SD. **Po0.002, unpaired test.
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affected body area skin involvement with much less erythema,
scale, crust, and alopecia compared with K14-mOVA control
mice receiving WT OT-I cells (Figure 4a and b). A dense
perivascular lymphocytic infiltrate dominated the dermis of
ears from WT OT-I–transferred K14-mOVA mice, obscuring
the dermal–epidermal junction with pronounced basal
vacuolar change and intercellular edema, while the overlying
cornified layer showed parakeratosis with a scaly crust;
features markedly reduced in the ear skin of CXCR3KO
OT-I–transferred K14-mOVA mice (Figure 4c). No significant
difference in the percentage of weight loss from initial weight
was observed in K14-mOVA mice receiving CXCR3KO
compared with those receiving WT OT-I cells (Figure 4d).
CXCR3 deficiency does not alter OT-I cell activation status or
effector function
We hypothesized that intrinsic CXCR3 deficiency on OT-I
cells would not impair their activation status or effector
function. FACS analysis examining the expression of CD25,
CD62L, and CD44 activation markers on OT-I cells collected
from the SDLNs and spleens of recipient K14-mOVA mice
after transfer of CXCR3KO or WT OT-I cells showed no
significant differences in activation phenotype on day 8; both
groups showed phenotypes of high CD25, low CD62L, and
high CD44 expression (Figure 5a and b).
Serum levels of IFN-g have been correlated with GVHD
severity (Yang et al., 2005). As OT-I cells are the principal
source of IFN-g expected in our model, we examined the
impact of CXCR3 deficiency on serum levels of IFN-g in K14-
mOVA mice that received either WT or CXCR3KO OT-I cells.
At day 5 post cell transfer, the mean plasma concentration of
IFN-g was not significantly different between the WT and
CXCR3KO OT-I groups (Supplementary Figure S2a online).
Intracellular staining for IFN-g and Granzyme-B in CXCR3KO
and WT OT-I cells from the SDLNs and spleens of K14-mOVA
mice at day 5 post OT-I transfer demonstrated that the effector
function was not significantly different (Supplementary Figure
S2b online). Indeed, no significant difference in CXCR3-KO or
WT OT-I cell cytotoxicity was observed in an in vitro
cytotoxicity assay (data not shown).
Collectively, the intact effector function of CXCR3KO OT-I
cells suggested retention of cytotoxic capacity in the absence
of CXCR3, indicating that the significant reduction of skin
disease was not attributable to impaired effector T-cell
function.
CXCR3 expression is an important determinant of trafficking of
OT-I cells to the skin
Guided by no observable qualitative deficiencies in
CXCR3KO OT-I cells, we hypothesized that if CXCR3 expres-
sion mediated the recruitment of OT-I cells to the skin, then
CXCR3KO and WT OT-I cells may exhibit differential migra-
tion and localization. CXCR3-deficient OT-I cells were detect-
able in both the SDLNs and spleens 5 days after transfer into
K14-mOVA mice, confirming that CXCR3 expression was not
required for initial effector OT-I cell influx into secondary
lymphoid organs, including the spleen and SDLNs (Figure 6a).
In accordance with other studies (Duffner et al., 2003;
Hildebrandt et al., 2004), we observed that CXCR3
deficiency altered the kinetics of T-cell expansion in
secondary lymphoid organs (Duffner et al., 2003;
Hildebrandt et al., 2004). At day 5, the number of donor
OT-I cells in the SDLNs and spleens of K14-mOVA mice that
received CXCR3KO OT-I cells was significantly greater
compared with control mice that received WT OT-I cells
(Figure 6a). In contrast, at day 8, the number of OT-I cells that
were recovered from the SDLNs of mice receiving WT OT-I
cells was significantly increased as compared with mice
receiving CXCR3KO OT-I cells, whereas a significantly greater
number of OT-I cells accumulated in the spleens of K14-
mOVA–Tg mice receiving CXCR3KO OT-I cells as opposed to
control WT OT-I cells (Figure 6a). Furthermore, consistent
with studies of CXCR3KO T cells in conditioned GVHD
models showing accumulation in the spleen (Hildebrandt
et al., 2004, Duffner et al., 2003), CXCR3KO OT-I cells
trafficked and primarily accumulated in the spleen, whereas
WT OT-I cells preferentially accumulated in the SDLNs.
Moreover, results suggested that even if OT-I cells showed
an activated phenotype, absence of CXCR3 on OT-I cells
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Figure 3. Decrease of OT-I cells in the skin-draining lymph nodes (SDLNs) is
associated with accumulation of OT-I cells in the skin of keratin 14–
membrane ovalbumin (K14-mOVA) mice. (a) Summary of flow cytometry data
of average percentages of GFPþOT-I cells in gated lymphocytes in SDLNs of
K14-mOVA mice 6–14 days after transfer of 1106 GFPþOT-I cells (n¼ 3–4
mice per day). Error bars indicate 1 SD. (b) Summary of fluorescence-activated
cell sorting analysis of skin-infiltrating GFPþOT-I cells in the ear skins of K14-
mOVA mice or control C57BL/6 mice at day 3, 5, and 13 following transfer of
1 106 GFPþOT-I cells (n¼ 3 mice/group/day). *Po0.05, **Po0.01,
unpaired t-test.
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inhibited trafficking to SDLNs. Results demonstrating
differential trafficking of CXCR3KO OT-I cells to the spleen,
away from the skin, in contrast to WT OT-I cell recruitment
primarily to the SDLNs en route to the skin, suggested that
CXCR3-mediated OT-I migration incited cutaneous
inflammation and target organ injury.
To determine whether ablation of CXCR3 expression on
OT-I cells limits OT-I recruitment to the skin, FACS analysis
was performed on skin lymphocyte suspensions from the ears
of K14-mOVA Tg mice 8 days after transfer of CXCR3KO
or WT OT-I cells. The frequencies of OT-I cells among
skin-infiltrating lymphocytes of K14-mOVA mice that received
CXCR3KO OT-I cells were significantly reduced compared
with control K14-mOVA mice that received WT OT-I cells
(Po0.01, Figure 6b). CXCR3 deficiency produced no qualita-
tive alteration in the nature of OT-I cells, with intact T-cell
activation and effector capabilities but impaired skin-directed
migration. These data indicate that CXCR3 has a functional
role in the skin-specific migratory pattern of OT-I cells.
DISCUSSION
We have demonstrated the functional significance of CXCR3
in the skin-selective migration of autoreactive OT-I T cells and
that the reduced pathogenicity of CXCR3KO OT-I cells reflects
the vital role of CXCR3 in optimal T-cell migration, not
effector function. Day 5 after OT-I transfer was punctuated
by upregulation of CXCL9 and CXCL10 mRNA expression
levels in the epidermis and preferential CXCR3 expression on
antigen-specific, autoreactive CD8 T cells. Indeed, even early
after adoptive transfer, GFPþOT-I cells can be detected and
they produce IFN-g that presumably induces CXCL9 and
CXCL10 by keratinocytes. We also showed that the reduction
of OT-I cells in the SDLNs of K14-mOVA mice coincided with
increased accumulation of GFPþOT-I cells in the skin
between day 5 and day 13 post-OT-I transfer. The temporal
association of CXCR3 upregulation on autoaggressive effector
T cells, induction of CXCR3 ligands in target-tissue epidermis,
and the subsequent accumulation of OT-I cells in the skin
suggested that CXCR3 expression imprints a pattern for skin-
selective homing of autoreactive T cells.
Abrogation of CXCR3 expression significantly compromised
the pathogenicity of autoreactive CD8þ OT-I cells, markedly
attenuating the development of GVHD-like skin lesions.
CXCR3-deficient donor T cell use in murine models of GVHD
has been shown to reduce the severity of pulmonary and
intestinal disease (Hildebrandt et al., 2004, Duffner et al.,
2003). Notably, we have previously demonstrated the
importance of interleukin (IL)-15, a cytokine shown to
upregulate CXCR3 expression on CD8þ T cells, in our
model as K14-mOVA mice on IL-15 KO or IL-15R KO
backgrounds were protected from skin disease after OT-I
transfer (Miyagawa et al., 2008, Norii et al., 2006). Although
clinical studies of GVHD patients have indirectly implicated
CXCR3 in acute GVHD pathogenesis, this study presents
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Figure 4. Absence of C-X-C motif chemokine receptor 3 (CXCR3) on OT-I donor cells markedly attenuates the severity of autoreactive skin disease.
(a, b) Photographs of K14-mOVA (keratin 14–membrane ovalbumin) mice taken on day 22 after transfer of CXCR3-knockout (CXCR3KO) or wild-type (WT) OT-I
cells. (c) Histology of the ears of K14-mOVA mice at day 14 after transfer of 5106 OT-I cells. Bar¼100mm. (d) Graph showing percentages of initial weight
loss after transfer of 5 106 CXCR3KO or WT OT-I cells into K14-mOVA mice (n¼7–9 mice/group). Error bars represent SD.
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evidence delineating how direct targeting of CXCR3 on
specific, autoreactive CD8 effector T cells reliably limits the
development of skin disease in a murine model of GVHD.
Strengthening our observations, and consistent with the
results of another group (Duffner et al., 2003), we
demonstrated that CXCR3 deficiency does not qualitatively
impair the intrinsic T-cell response to antigen, as reflected in
preserved activation and effector functions, but instead
imparts a migratory deficit. However, CXCR3KO OT-I cells
successfully trafficked to the SDLN and spleen, indicating that
CXCR3 was not required for OT-I cell localization to the
SDLN and spleen in our model. Although CXCR3KO OT-I
cells displayed enhanced kinetics of expansion at day 5, this
increase in expansion did not compensate for the impact of
CXCR3 deficiency on differential localization of OT-I cells as
evinced by the reduced severity of CXCR3KO OT-I–induced
skin disease. In contrast to the dearth of CXCR3KO OT-I cells
observed in the skin and SDLNs, the abundance of CXCR3KO
OT-I cells in the spleens of K14-mOVA mice suggested
differential patterns of T-cell trafficking underlying attenuated
skin injury. Moreover, CXCR3-dependent migration was
critical for optimal infiltration of autoreactive T cells to the
skin as analysis of skin-infiltrating lymphocytes demonstrated
a significant reduction in the proportion of CXCR3-KO OT-I
cells infiltrating the skin. Nonetheless, some OT-I cells
were successfully recruited to the skin, perhaps reflecting
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functionally redundant chemokine activity. Another result that
informs our understanding of the role of CXCR3 in this model
is the demonstration that CXCR3KO OT-I cells do not
influence the magnitude and course of weight loss observed
after transfer to K14-mOVA mice. The mechanism underlying
weight loss in our model is not understood, but it is thought
to be due to decreased oral intake caused by mucosal
inflammation. Chemokine biology is characterized by
localized, tissue-specific expression of chemokines directing
leukocyte trafficking (Lonsdorf et al., 2009). Thus, OT-I cell
homing to esophageal-stratified squamous epithelia may not
require CXCR3 and, instead, may involve other specific
chemokines. It is unlikely that other internal organs are
targeted as we have not identified OVA-specific message in
the intestines, liver, or lungs in these transgenic mice (Shibaki
et al., 2004) nor have we seen any inflammatory changes in
these tissues. Alternatively, weight loss may also be primarily
driven by cytokine production and systemic inflammation,
which seem to be unaltered as a result of CXCR3 deficiency,
based on data suggesting unperturbed effector function in
CXCR3KO OT-I cells.
Collectively, our studies in a murine model of GVHD
suggest a functional interface between epidermal CXCL9–10
expression and the epidermotropism of CXCR3þ T cells
during GVHD-like skin disease. We have demonstrated that
intradermal injection of IFN-g induces CXCL9 and CXCL10
mRNA expression levels in the epidermis of K14-mOVA mice
(data not shown). Moreover, a recent study demonstrated that
treatment with a Janus-activated kinase inhibitor directly
inhibited IFN-g-induced apoptosis of human keratinocytes
and effectively prevented GVHD-like skin lesions in our
model in association with the inhibition of epidermal CXCL9
and CXCL10 expression (Okiyama et al., 2014). The kinetics
of CXCL9 and CXCL10 expression show IFN-g mRNA
induction in the epidermis by 2 days following OT-I transfer,
suggesting that early molecular events serve as stimuli that
precede their induction. The process of lymphocyte
recirculation during which leukocytes such as OT-I cells
exhibit a basal level of entry into uninflamed tissues likely
incites the cascade that perpetuates CXCR3-mediated
leukocyte influx (Ley and Kansas, 2004; Wysocki et al.,
2005; Taqueti et al., 2006). Keratinocytes function as
accessory cells for the presentation of endogenous self-
antigen expressed in the epidermis to CD8þ T cells to
induce priming (Kim et al., 2009). We propose that naive
effector OT-I cells encounter keratinocytes that are cross-
presenting OVA peptide, activating these CD8þ T cells and
initiating an inflammatory milieu and secretion of cytokines
that leads to keratinocyte damage. Subsequently, expression of
IFN-g-inducible chemokines, CXCL9 and CXCL10, promotes
recruitment of CXCR3-expressing T cells through a CXCR3
inflammatory loop wherein further effector T-cell recruitment
and IFN-g secretion amplifies infiltration of CXCR3þ effector
T cells (Groom and Luster, 2011).
Reshef et al. (2012) recently demonstrated that treatment
with a CCR5 (C-C motif chemokine receptor 5) inhibitor
resulted in decreased incidence of visceral GVHD.
Interestingly, the incidence of cutaneous GVHD was
unaltered with CCR5 inhibitor treatment, suggesting that
unique chemokine signaling pathways may be involved in
skin migration and emphasizing the influence of tissue-
specific chemokine expression in the design of chemotaxis
inhibitors (Reshef et al., 2012). CXCR3 inhibitors have shown
their uses in many animal models of disease (Wijtmans et al.,
2008). A phase II clinical trial for a CXCR3 inhibitor in the
treatment of psoriasis was discontinued due to lack of efficacy
despite a favorable toxicity profile (Jenh et al., 2012).
Ultimately, antibody-mediated immunodepletion of pathogenic
effector T-cell populations could be developed as a
therapeutic modality based on discernable patterns of
leukocyte trafficking and CXCR3 expression. Characterizing
the preferential expression of specific chemokine receptors,
such as CXCR3, on discrete leukocyte subsets in inflammatory
diseases may facilitate the development of selective
immunomodulators combining efficacy and safety.
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Figure 6. Effect of C-X-C motif chemokine receptor 3 (CXCR3) expression on
the number of OT-I cells in the spleens and skin-draining lymph nodes
(SDLNs) and proportions of skin-infiltrating lymphocytes. K14-mOVA (keratin
14–membrane ovalbumin) mice received 5106 CXCR3-knockout
(CXCR3KO) or wild-type (WT) OT-I cells. (a) SDLN cells and splenocytes were
harvested from K14-mOVA mice that received 5106 CXCR3KO or WT OT-I
cells (n¼ 4 mice/group per day) and were counted and characterized by flow
cytometry. Error bars depict±SEM. Po0.05, Mann–Whitney test.
(b) Fluorescence-activated cell sorting analysis was performed in ear skin–
infiltrating lymphocytes of K14-mOVA mice (n¼ 3 mice/group) 8 days
after transfer of 5106 CXCR3KO or WT OT-I cells. Bars indicate mean
percentages of CD3þCD4CD8þVa2þVb5þ cells of total live-gated
lymphocytes. Error bars depict SD. *Po0.05, **Po0.01, unpaired t-test.
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MATERIALS AND METHODS
Adoptive transfer
Description of the mice used in this study is included in
Supplementary Methods online. Single-cell suspensions were pre-
pared from pooled LNs (inguinal LNs, axillary LNs, mesenteric LNs)
of OT-I with Rag1-KO-background, GFPþOT-I or CXCR3KO OT-I
mice. CD8þ cells were purified from the pooled LN cells via Mouse
CD8 T-cell columns (R&D Systems, Minneapolis, MN). One or five
million OT-I, GFPþOT-I, or CXCR3KO OT-I cells were injected
intravenously into K14-mOVA mice. Their weights and clinical status
were monitored daily for 14 days.
Epidermal sheets, RNA extraction, and qRT-PCR
For epidermal sheets, mouse ears were separated into dorsal and
ventral halves and incubated for 20 minutes at 37 1C on 3.8%
ammonium thiocyanate (Sigma-Aldrich, St Louis, MI). Epidermal
mRNA was extracted using RNeasy Lipid Tissue Kit (QIAGEN, Clarita,
CA) and processed as per the manufacturer’s protocols using the RT2
Profiler PCR Array System with the Mouse Inflammatory Cytokines
and Receptors array (QIAGEN).
Collection of skin-infiltrating cells
Ears were diced, digested in RPMI 1640 (Invitrogen) containing
2 mg ml 1 Liberase TL (Roche, Indianapolis, IN) at 4 1C overnight
under gentle agitation, and were incubated at 37 1C for 30 minutes in
RPMI 1640 (Invitrogen) with 0.04 mg ml 1 DNase I (Sigma-Aldrich).
Suspensions were dissociated by pipetting and filtered through
70- and 100-mm filters before FACS analysis.
Flow cytometry
Single-cell suspensions were prepared from the superficial LNs
(inguinal LNs, axillary LNs, and cervical LNs), spleens, and ear skins
of K14-mOVA mice on indicated days after OT-I cell transfer.
Antibodies used are listed in Supplementary Materials online.
Histology
Tissues were fixed in 10% neutral-buffered formalin, embedded in
paraffin, sectioned, and then stained with hematoxylin and eosin
using the standard protocols (American HistoLabs, Rockville, MD).
Statistics
Analyses were conducted using Prism (Graphpad, San Diego, CA).
Student’s t-test and the Mann–Whitney test were used for compar-
isons. A P-value of o0.05 was considered statistically significant.
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